Levodopa/karbidopa/entacapone karşı levodopa/benserazid artı Parkinson hastalığı olan Çinli hastalarda pramipeksol aşınmış.

Araştırma özeti

Aşağıdaki metin kaynak makalenin lisansı doğrulanmış orijinal özetidir. cc by

ObjectiveTo compare the efficacy and safety of direct switch from levodopa/benserazide (LB) to levodopa/carbidopa/entacapone (LCE) versus LB plus pramipexole (PPX) in Chinese patients with Parkinson's disease (PD) experiencing wearing off (WO).MethodsIn this multicenter, prospective, randomized, open-label, observational study, 140 patients with PD experiencing WO who had been on stable LB treatment were enrolled and randomized 3:2 to receive LCE (84) or LB + PPX (56) treatment for 8 weeks. The primary endpoint was change in the daily "OFF" time from baseline. Change in the daily "ON" time was also assessed. Treatment-emergent adverse events (TEAEs) were recorded.ResultsSeventy-nine patients in the LCE group and 49 patients in the PPX group completed the study. Both LCE and PPX shortened the patients' daily OFF time significantly after 8 weeks (-1.76 ± 1.70 h, p p p = 0.414). Correspondingly, both the LCE group and the PPX group had significantly increased daily ON time (1.62 ± 1.59 h, p p p = 0.412). Both treatments improved the patients' WO symptoms, sleep quality, depression and quality of life. Six (7.59%) patients in the LCE group and 7 (14.29%) patients in the PPX group reported TEAEs, all of which were mild and tolerable. One patient in the LCE group and 2 patients in the PPX group experienced mild dyskinesia.ConclusionLCE and LB + PPX were both effective, safe and tolerable in treating patients with PD who experienced WO.

İlgili konular